These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 35462552)

  • 21. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
    Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
    Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
    Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
    Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
    Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
    Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
    Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
    BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
    Nishimura T; Velaga R; Masuda N; Kawaguchi K; Kawaguchi S; Takada M; Maeshima Y; Tanaka S; Kikawa Y; Kadoya T; Bando H; Nakamura R; Yamamoto Y; Ueno T; Yasojima H; Ishiguro H; Morita S; Ohno S; Haga H; Matsuda F; Ogawa S; Toi M
    Cancer Sci; 2024 Dec; 115(12):3928-3942. PubMed ID: 39375938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
    Mutai R; Kuchuk I; Goldshtein A; Yerushalmi R; Rotem O; Maisel Lotan A; Bdolah-Abram T; Gabizon A; Goldvaser H
    Breast Cancer Res Treat; 2024 Jun; 205(2):241-248. PubMed ID: 38345692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
    Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
    Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
    Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.